Acta Biochimica et Biophysica Sinica · 2010 · 36 citations · 11 references
MedicineCancer BiologyOncologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis RegulationApoptosis ResistanceApoptotic SignalingBladder CancerApoptosis TargetingApoptotic Signaling In CancerCancer Cell ApoptosisCell Growth RegulationGene-targeted TherapySurvivin InhibitionSynergistic ImpactsSynergistic Inhibitor Effects
Livin, X-linked inhibitor of apoptosis (XIAP), and Survivin are three well-known inhibitors of apoptosis almost exclusively over-expressed in cancer cells and are considered potent targets for cancer treatment. In the present study, we found that Livin, XIAP, and Survivin were simultaneously expressed in bladder cancer cells. We speculated that Livin, XIAP, and Survivin might have synergistic effects on cell growth and apoptosis. Our results confirmed that combined knockdown of all these three genes can synergistically inhibit the proliferation and transformation ability of high-grade bladder cancer T24 cells and promote the cell apoptotic sensitivity to chemotherapy. Furthermore, combined knockdown of Livin, XIAP, and Survivin can markedly increase the abundance of active caspase-3, active caspase-7, active caspase-9, and cytosolic Smac. Our findings imply that combined silencing of Livin, XIAP, and Survivin may be a potent multitargeted gene therapy for bladder cancer.
11
Livin, a Novel Inhibitor of Apoptosis Protein Family Member
Gary Kasof, Bruce Gomes · Journal of Biological Chemistry · 2001 · 452 citations · Full text
Why target apoptosis in cancer treatment?
Shailaja Kasibhatla, Ben Tseng · PubMed · 2003 · 354 citations
Medicine, Cancer Biology, Oncology +17
Jordan M. Cummins, Manu Kohli, Carlo Rago et al. · Cancer Research · 2004 · 198 citations